European Investor
18 Apr 2026, 20:25
Gilead Sciences announced that it has secured all required regulatory approvals for its acquisition of Arcellx, clearing a key hurdle toward completing the transaction.
The approval process concluded after clearance from the Australian Competition and Consumer Commission, with the final waiting period set to expire on April 27, 2026. The company also confirmed that other international regulatory reviews have been completed, meaning all approval conditions will be satisfied once the waiting period ends.
Gilead has extended its tender offer for Arcellx shares to April 27, maintaining the offer at $115 per share in cash plus a contingent value right tied to future sales milestones of its lead therapy. As of mid-April, approximately 17.5% of shares had been tendered.
The deal remains subject to customary closing conditions, including majority shareholder participation, but positions Gilead to strengthen its oncology pipeline and expand its capabilities in cell therapy as it moves closer to completing the acquisition.
Business Wire
The approval process concluded after clearance from the Australian Competition and Consumer Commission, with the final waiting period set to expire on April 27, 2026. The company also confirmed that other international regulatory reviews have been completed, meaning all approval conditions will be satisfied once the waiting period ends.
Gilead has extended its tender offer for Arcellx shares to April 27, maintaining the offer at $115 per share in cash plus a contingent value right tied to future sales milestones of its lead therapy. As of mid-April, approximately 17.5% of shares had been tendered.
The deal remains subject to customary closing conditions, including majority shareholder participation, but positions Gilead to strengthen its oncology pipeline and expand its capabilities in cell therapy as it moves closer to completing the acquisition.
Business Wire